JP2017536119A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536119A5
JP2017536119A5 JP2017526918A JP2017526918A JP2017536119A5 JP 2017536119 A5 JP2017536119 A5 JP 2017536119A5 JP 2017526918 A JP2017526918 A JP 2017526918A JP 2017526918 A JP2017526918 A JP 2017526918A JP 2017536119 A5 JP2017536119 A5 JP 2017536119A5
Authority
JP
Japan
Prior art keywords
lna
nucleosides
oligonucleotide according
nucleoside
phosphorothioate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536119A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/076967 external-priority patent/WO2016079181A1/en
Publication of JP2017536119A publication Critical patent/JP2017536119A/ja
Publication of JP2017536119A5 publication Critical patent/JP2017536119A5/ja
Pending legal-status Critical Current

Links

JP2017526918A 2014-11-19 2015-11-18 キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド Pending JP2017536119A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP14193887.8 2014-11-19
EP14193887 2014-11-19
EP14198167 2014-12-16
EP14198167.0 2014-12-16
EP15182401 2015-08-25
EP15182401.8 2015-08-25
EP15191074.2 2015-10-22
EP15191075 2015-10-22
EP15191074 2015-10-22
EP15191076 2015-10-22
EP15191076.7 2015-10-22
EP15191075.9 2015-10-22
PCT/EP2015/076967 WO2016079181A1 (en) 2014-11-19 2015-11-18 Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages

Publications (2)

Publication Number Publication Date
JP2017536119A JP2017536119A (ja) 2017-12-07
JP2017536119A5 true JP2017536119A5 (enExample) 2018-11-15

Family

ID=54608516

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526918A Pending JP2017536119A (ja) 2014-11-19 2015-11-18 キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド
JP2017526905A Pending JP2017536366A (ja) 2014-11-19 2015-11-18 Lnaキラルホスホロチオエート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017526905A Pending JP2017536366A (ja) 2014-11-19 2015-11-18 Lnaキラルホスホロチオエート

Country Status (4)

Country Link
US (2) US20180016575A1 (enExample)
EP (2) EP3220921A1 (enExample)
JP (2) JP2017536119A (enExample)
WO (2) WO2016079183A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616051T3 (es) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 官能化核酸の合成のための方法
US9982257B2 (en) 2012-07-13 2018-05-29 Wave Life Sciences Ltd. Chiral control
MX356830B (es) 2012-07-13 2018-06-15 Shin Nippon Biomedical Laboratories Ltd Adyuvante de acido nucleico quiral.
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
DK3094728T3 (da) 2014-01-16 2022-05-16 Wave Life Sciences Ltd Kiralt design
JP6718872B2 (ja) 2014-12-17 2020-07-08 プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップProQR Therapeutics II B.V. 標的化rna編集
US10793855B2 (en) * 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US10955407B2 (en) 2015-10-22 2021-03-23 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
EP3430021A1 (en) * 2016-03-18 2019-01-23 Roche Innovation Center Copenhagen A/S Acyl-protected l-lna-guanosine monomers
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US11479818B2 (en) * 2016-06-17 2022-10-25 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
US11105794B2 (en) * 2016-06-17 2021-08-31 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
JP7074345B2 (ja) 2016-06-22 2022-05-24 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 一本鎖rna編集オリゴヌクレオチド
IL264923B2 (en) 2016-09-01 2025-07-01 Proqr Therapeutics Ii Bv Single-stranded RNA-editing oligonucleotides with chemical modifications
JP7115669B2 (ja) 2016-11-14 2022-08-09 学校法人東京理科大学 重合性化合物、化合物、及び、ボラノホスフェートオリゴマーの製造方法
CN110088113A (zh) * 2016-11-23 2019-08-02 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法
US20190345496A1 (en) * 2017-01-13 2019-11-14 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating relb expression
US20190367920A1 (en) * 2017-01-13 2019-12-05 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
EP3694995A1 (en) 2017-10-13 2020-08-19 Roche Innovation Center Copenhagen A/S Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
CN111511914B (zh) * 2017-10-16 2023-11-17 豪夫迈·罗氏有限公司 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
SMT202500334T1 (it) 2017-12-01 2025-11-10 Texas A & M Univ Sys Trattamento antisenso della sindrome di angelman
BR112020010090A2 (pt) * 2017-12-22 2020-11-03 Roche Innovation Center Copenhagen A/S oligonucleotídeo gapmer, sal farmaceuticamente aceitável do mesmo, conjugado, composição farmacêutica e uso dos mesmos
TW201929870A (zh) * 2017-12-22 2019-08-01 丹麥商羅氏創新中心哥本哈根有限公司 包含二硫代磷酸酯核苷間連結之寡核苷酸
EP3728590B1 (en) * 2017-12-22 2025-07-02 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
MX2020007439A (es) * 2018-01-12 2020-09-14 Bristol Myers Squibb Co Oligonucleotidos antisentido que actuan sobre alfa-sinucleina y usos de estos.
CA3088112A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN112236438B (zh) 2018-04-13 2024-10-15 百时美施贵宝公司 基于磷(v)的试剂,其制备方法,以及其在制备立体限定的有机磷(v)化合物中的用途
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
CA3247235A1 (en) 2018-07-03 2025-11-29 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression
EP3819378A4 (en) * 2018-07-04 2022-09-14 Aichi Medical University OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES
MX2021009950A (es) * 2019-02-20 2021-09-21 Roche Innovation Ct Copenhagen As Oligonucleotidos gapmeros de fosfonoacetato.
US11466274B2 (en) 2019-05-31 2022-10-11 Aligos Therapeutics, Inc. Modified gapmer oligonucleotides and methods of use
CN115244061A (zh) 2020-01-16 2022-10-25 百时美施贵宝公司 试剂及其用于模块化对映发散性合成c-p键的用途
KR20250069923A (ko) 2022-09-19 2025-05-20 브리스톨-마이어스 스큅 컴퍼니 신규한 인(v)-기반 시약, 이의 제조 방법, 및 입체-규정 유기인(v) 화합물의 제조에 있어서의 그의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
EP2410053B2 (en) * 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
US9982257B2 (en) * 2012-07-13 2018-05-29 Wave Life Sciences Ltd. Chiral control
MX2015009056A (es) * 2013-01-30 2015-10-05 Hoffmann La Roche Conjugados de oligonucleotidos de acido nucleico bloqueado y carbohidratos.

Similar Documents

Publication Publication Date Title
JP2017536119A5 (enExample)
JP2017536366A5 (enExample)
JP2020058368A5 (enExample)
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
JP2018512110A5 (enExample)
JP2020022483A5 (enExample)
JP2018512041A5 (enExample)
JP2013226147A5 (enExample)
JP2017505623A5 (enExample)
JP2020532961A5 (enExample)
JP2012510297A5 (enExample)
JP2013511990A5 (enExample)
JP2021505129A5 (enExample)
HRP20210315T1 (hr) Oligonukleotidi za smanjenje ekspresije pd-l1
JP2009524419A5 (enExample)
JP2016530294A5 (enExample)
JP2018530530A5 (enExample)
JP2016171800A5 (enExample)
JP2019503394A5 (enExample)
JP2013535212A5 (enExample)
JP2014511686A5 (enExample)
JP2012105686A5 (enExample)
JP2018531037A5 (enExample)
JP2009532044A5 (enExample)
JP2018525357A5 (enExample)